UCLA in the News January 25, 2022
Highlights from NPR, the Wall Street Journal, the New York Times and others.
Stay updated with breaking news from John Mafi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Highlights from NPR, the Wall Street Journal, the New York Times and others.
A UCLA-led cost analysis of the controversial new Alzheimer’s disease drug aducanumab shows that ancillary care services, such as additional MRIs and
Americans' use of common outpatient health services dipped sharply at the outset of the COVID-19 pandemic, then rebounded to near-normal levels by the end of 2020, only to decline again during the second surge in January–February 2021, according to a new UCLA-led study.
Research brief: Additional services to monitor the drug’s potential side effects account for nearly 20% of its total costs, a UCLA-led study shows.
While the situation improved, economically disadvantaged patients were far less likely to return to using services at normal, pre-pandemic levels.